missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ PD-L1 Polyclonal Antibody
Description
Recommended positive controls: A431, MDA-MB-231, MDA-MB-231 (24 μg/mL Tunicamycin treatment for 16 hr), MDA-MB-231, A549 (100 ng/mL IFN-gamma treatment for 48 hr), A431 (100 ng/mL IFN-gamma treatment for 48 hr). Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.
Programmed death receptor ligand 1 (PD-L1, also called B7-H1) is a recently described B7 family member. To date, one specific receptor has been identified that can be ligated by PD-L1. This receptor, programmed death receptor 1 (PD-1), has been shown to negatively regulate T-cell receptor (TCR) signaling. Upon ligating its receptor, PD-L1 has been reported to decrease TCR-mediated proliferation and cytokine production. PD-L1 expression was found to be abundant on many murine and human cancers and could be further up-regulated upon IFN-gamma stimulation. Thus, PD-L1 might play an important role in tumor immune evasion.
Specifications
Specifications
| Antigen | PD-L1 |
| Applications | Flow Cytometry, Immunohistochemistry (Frozen), Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry |
| Classification | Polyclonal |
| Concentration | 0.97 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 20% glycerol and 0.025% ProClin 300; pH 7 |
| Gene | Cd274 |
| Gene Accession No. | Q9NZQ7 |
| Gene Alias | A530045L16Rik; B7 homolog 1; B7-H; B7h1; B7-H1; Cd274; CD274 antigen; CD274 molecule; PDCD1 ligand 1; Pdcd1l1; Pdcd1lg1; Pdl1; PD-L1; pdl-1; Programmed cell death 1 ligand 1; programmed death ligand 1; RGD1566211; sCD274; soluble CD274; soluble PD L1; sPD L1 |
| Gene Symbols | Cd274 |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?